October 1, 2017Open Access

Treatment of Glioblastoma

Key Points

Key points are not available for this paper at this time.

Abstract

-methylguanine-DNA methyltransferase ( MGMT) promoter methylation. We review updates in management of newly diagnosed and recurrent glioblastoma, as well as common difficulties in management, such as pseudoprogression and pseudoresponse. Ongoing translational research in targeted therapy and immunotherapy is briefly discussed.

Bookmark

View Full Paper

Cite This Study

Nam et al. (Sun,) studied this question.

synapsesocial.com/papers/69ff4c64413f0c047f2d6108 https://doi.org/https://doi.org/10.1200/jop.2017.025536

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies2013 · 355 citations
2Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline2017 · 194 citations
3Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma2017 · 1,180 citations
4Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial2014 · 1,019 citations
5Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma2014 · 2,504 citations

Bookmark

View Full Paper